Per- and polyfluoroalkyl substances (PFAS) have become a focal point of regulatory, environmental, and commercial scrutiny in Europe. While PFAS were historically valued for their functional performance in cosmetics, particularly in long-lasting, water-resistant, and sensory-enhancing applications, the European regulatory approach has shifted toward class-based restriction and long-term phase-out.

You have probably heard the headline that microplastics are everywhere: in the ocean, in the air, in table salt, and yes, in human blood and placentas. But for regulatory affairs professionals, the conversation needs to go much further than awareness. This article is structured in two acts: an explainer for anyone new to the topic, followed by an operational deep dive into the regulatory obligations taking shape right now.